Change in healthcare utilization and costs following initiation of benzodiazepine therapy for long-term treatment of generalized anxiety disorder: A retrospective cohort study

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Berger, Ariel ^a   Edelsberg, John ^a   Treglia, Michael ^b   Alvir, Jose Ma J ^b   Oster, Gerry ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b PFIZER INC   (United States)

Author keywords

Anxiety Disorders; Benzodiazepines; Costs and Cost Analysis; Healthcare Research; Utilization

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ESCITALOPRAM; LORAZEPAM; OXAZEPAM; PAROXETINE; SERTRALINE; VENLAFAXINE;

ACCIDENT; ADD ON THERAPY; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG DEPENDENCE; FALLING; FEMALE; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT CARE; PATIENT CARE; PRESCRIPTION; SEDATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; COHORT ANALYSIS; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH; LONG-TERM CARE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84867678033     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-177     Document Type: Article

References (47)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Text Revision. American Psychiatric Association, Washington, DC, 4, American Psychiatric Association.
2. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 2000, 176:544-549. 10.1192/bjp.176.6.544, 10974960.
3. Kessler R, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age of onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:593-602. 10.1001/archpsyc.62.6.593, 15939837.
4. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005, 15:445-452. 10.1016/j.euroneuro.2005.04.010, 15951160.
5. Wittchen HU, Carter RM, Pfister H, Montgomery SA, Kessler RC. Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 2000, 15:319-328. 10.1097/00004850-200015060-00002, 11110007.
6. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures: Results from the WHO collaborative study on psychological problems in general health care. JAMA 1994, 272:1741-1748. 10.1001/jama.1994.03520220035028, 7966922.
7. Wittchen HU. Generalized anxiety disorder: Prevalence, burden, and cost to society. Depress Anxiety 2002, 16:162-171. 10.1002/da.10065, 12497648.
8. Munk-Jorgensen P, Allgulander C, Dahl AA, Foldager L, Holm M, Rasmussen I, Virta A, Huuhtanen MT, Wittchen HU. Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden. Psychiatr Serv 2006, 57:1738-1744. 10.1176/appi.ps.57.12.1738, 17158488.
9. Baldwin DS, Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 2005, 8:293-302. 10.1017/S1461145704004870, 15576000.
10. National Institute for Health and Clinical Excellence (NICE) Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care (partial update). NICE guideline, draft for consultation, July 2010. World Wide Web 2010, http://www.nice.org.uk/nicemedia/live/12147/49816/49816.pdf. Accessed August 25, 2011, National Institute for Health and Clinical Excellence (NICE).
11. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008, 9:248-312. 10.1080/15622970802465807, 18949648.
12. Cumming RG, LeCouteur DG. Benzodiazepines and risk of hip fractures in older people: A review of the evidence. CNS Drugs 2003, 17:825-837. 10.2165/00023210-200317110-00004, 12921493.
13. Petrovic M, Mariman A, Warie H, Afschrift M, Pevernagie D. Is there a rationale for prescription of benzodiazepines in the elderly? Review of the literature. Acta Clin Belg 2003, 58:27-36.
14. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: Incidence, prevention and management. Drug Saf 1999, 21:101-122. 10.2165/00002018-199921020-00004, 10456379.
15. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported associated. Can Fam Physician 1998, 44:799-808. 2277821, 9585853.
16. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993, 328:1398-1405. 10.1056/NEJM199305133281907, 8292115.
17. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry 2003, 64:24-29.
18. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003, 8:53-61.
19. Kaplan ME, DuPont RL. Benzodiazepines and anxiety disorders: A review for the practicing physician. Curr Med Res Opin 2005, 21:941-950. 10.1185/030079905X48401, 15969894.
20. Lader M. Effectiveness of benzodiazepines: Do they work or not?. Expert Rev Neurother 2008, 8:1189-1191. 10.1586/14737175.8.8.1189, 18671662.
21. Beers MH, Ouslander JG, Rollinger I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991, 151:1825-1832. 10.1001/archinte.1991.00400090107019, 1888249.
22. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: An update. Arch Intern Med 1997, 157:1531-1536. 10.1001/archinte.1997.00440350031003, 9236554.
23. Zhan C, Sangl J, Bierman AS, Miller MR, Friedman B, Wickizer SW, Meyer GS. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001, 286:2823-2829. 10.1001/jama.286.22.2823, 11735757.
24. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 1990, 90:1467-1470.
25. Tamblyn R, Abrahamowicz M, Du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005, 53:233-241. 10.1111/j.1532-5415.2005.53108.x, 15673346.
26. Trewin VF, Lawrence CJ, Veitch GB. An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly. J Clin Pharm Ther 1992, 17:129-133.
27. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fractures. Osteoporos Int 2006, 17:807-816. 10.1007/s00198-005-0065-y, 16520889.
28. Stenbacka M, Jannson B, Leifman A, Romelsjo A. Associated between use of sedatives or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls: A longitudinal general population study. Alcohol 2002, 28:9-16. 10.1016/S0741-8329(02)00223-9, 12377356.
29. Pariente A, Dartigues JF, Benichou J, Letenneur L, Moore N, Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008, 25:61-70. 10.2165/00002512-200825010-00007, 18184030.
30. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, MacDonald TM. Association of road-traffic accidents with benzodiazepine use. Lancet 1998, 352:1331-1336. 10.1016/S0140-6736(98)04087-2, 9802269.
31. Chang CM, We UC, Chang IS, Lin KM. Benzodiazepine and risk of hip fractures in older people: A nested case-control study in Taiwan. Am J Geriatr Psych 2008, 16:686-692.
32. Rapoport MJ, Lanctot KL, Streiner DL, Bedard M, Vingilis E, Murray B, Schaffer A, Shulman KI, Herrmann N. Benzodiazepine use and driving: A meta-analysis. J Clin Psychiatry 2009, 70:663-673. 10.4088/JCP.08m04325, 19389334.
33. Barker MJ, Greenwood KM, Jackson M, Crowe SF. An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc 2005, 11:281-289.
34. Puustinen J, Nurminen J, Kukola M, Vahlberg T, Laine K, Kivela SL. Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: A non-randomised clinical study in the elderly. Drugs Aging 2007, 24:1045-1059. 10.2165/00002512-200724120-00007, 18020536.
35. Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009, 37:177-183. 10.1097/CCM.0b013e318192fcf9, 2700732, 19050611.
36. Ried LD, Johnson RE, Gettman DA. Benzodiazepine exposure and functional status in older people. J Am Geriatr Soc 1998, 46:71-76.
37. Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE, Landerman LR, Pieper CF, Blazer DG, Cohen HJ. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther 1998, 64:684-692. 10.1016/S0009-9236(98)90059-5, 9871433.
38. Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, Dartigues JF, Moride Y. Benzodiazepine use and risk of dementia: A nested case-control study. J Clin Epidemiol 2002, 55:314-318. 10.1016/S0895-4356(01)00453-X, 11864804.
39. Baldwin DS, Waldman S, Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 2011, 14:697-710. 10.1017/S1461145710001434, 21211105.
40. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005, 196:567-596.
41. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, Stein DJ, Wittchen HU. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 2001, 62:53-58.
42. Berger A, Edelsberg J, Bollu V, Alvir JMJ, Dugar A, Joshi AV, Oster G. Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: A retrospective cohort study. BMC Psychiatry 2011, 11:193. 10.1186/1471-244X-11-193, 3266199, 22151689.
43. Berger A, Edelsberg J, Bollu V, Alvir JMJ, Dugar A, Joshi AV, Oster G. Healthcare utilization and costs in patients with generalized anxiety disorder initiating add-on therapy with benzodiazepines. Health Outcomes Res Med 2012, 3:e45-e54.
44. Zohar J, Westenberg HG. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scan 2000, 101:39-49.
45. Hoffman EJ, Mattew SJ. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med 2008, 75:248-262. 10.1002/msj.20041, 18704983.
46. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr 2005, 10:49-56.
47. Vasile RG, Bruce SE, Goisman RM, Pagano M, Keller MB. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 2005, 22:59-67. 10.1002/da.20089, 3272770, 16094662.